

AMENDMENTS TO THE CLAIMS:

For the Office's convenience, Applicants present all claims with status indicator in compliance with the practice guidelines for making amendments under 37 C.F.R. §1.121(c) (1). Please amend the claims to read as follows:

1. (Currently Amended) An antisense compound 15 to 30 nucleobases in length targeted to a nucleic acid molecule encoding apolipoprotein(a), wherein said compound is at least 94% complementary to nucleotides 12380-12438~~12380-13493~~ as set forth in SEQ ID NO: 4.
2. (Canceled)
3. (Previously Presented) The antisense compound of claim 1 comprising an antisense oligonucleotide.
- 4.-5. (Canceled)
6. (Previously Presented) The antisense compound of claim 3 comprising a chimeric antisense oligonucleotide.
7. (Canceled)
8. (Previously Presented) The antisense compound of claim 1 having at least one modified internucleoside linkage, sugar moiety, or nucleobase.
9. (Previously Presented) The antisense compound of claim 1 having at least one 2'-O-methoxyethyl sugar moiety.
10. (Previously Presented) The antisense compound of claim 1 having at least one phosphorothioate internucleoside linkage.
11. (Previously Presented) The antisense compound of claim 1 having at least one 5-methylcytosine.
- 12.-16. (Canceled)

17. (Original) The antisense compound of claim 1 which is single-stranded.

18.-49. (Canceled)

50. (Currently Amended) An antisense compound 15 to 30 nucleobases in length targeted to a nucleic acid molecule encoding apolipoprotein(a), wherein said compound is at least 90% complementary to nucleotides 12380-12438~~12380-13493~~ as set forth in SEQ ID NO: 4 and wherein the antisense compound comprises at least 8 contiguous nucleobases of SEQ ID NO: 87.

51. (Canceled)

52. (Previously Presented) The antisense compound of claim 50, wherein the antisense compound comprises SEQ ID NO: 87.

53. (Previously Presented) The antisense compound of claim 50, wherein the antisense compound consists of SEQ ID NO: 87.

54. (Previously Presented) The antisense compound of claim 1, wherein the antisense compound is at least 95% complementary to SEQ ID NO: 4.

55. (Previously Presented) The antisense compound of claim 1, wherein the antisense compound is 100% complementary to SEQ ID NO: 4.

56. (Previously Presented) The antisense compound of claim 1, wherein the antisense compound is 20 nucleobases in length.

57. (Previously Presented) A chimeric antisense oligonucleotide 15 to 30 nucleobases in length targeted to a nucleic acid molecule encoding apolipoprotein(a), wherein said chimeric antisense oligonucleotide is at least 90% complementary to nucleotides 12380-12438~~12380-13493~~ as set forth in SEQ ID NO: 4.

58. (Previously Presented) The chimeric antisense oligonucleotide of claim 57, wherein said chimeric antisense oligonucleotide comprises a 2'-deoxynucleotide gap segment positioned between a 5' wing segment and a 3' wing segment.

59. (Previously Presented) The chimeric antisense oligonucleotide of claim 58, wherein each nucleotide of each wing segment comprises a modified sugar moiety.

60. (Previously Presented) The chimeric antisense oligonucleotide of claim 59, wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

61. (Previously Presented) The chimeric antisense oligonucleotide of claim 59, wherein the modified sugar moiety is a bicyclic nucleic acid sugar moiety.

62. (Previously Presented) The chimeric antisense oligonucleotide of claim 57, wherein each internucleoside linkage is a phosphorothioate internucleoside linkage.

63. (Previously Presented) The chimeric antisense oligonucleotide of claim 57, wherein each cytosine is a 5-methylcytosine.

64. (Previously Presented) The chimeric antisense oligonucleotide of claim 57, wherein the chimeric antisense oligonucleotide is at least 95% complementary to SEQ ID NO: 4.

65. (Previously Presented) The chimeric antisense oligonucleotide of claim 57, wherein the chimeric antisense oligonucleotide is 100% complementary to SEQ ID NO: 4.

66. (Previously Presented) The chimeric antisense oligonucleotide of claim 57, wherein the chimeric antisense oligonucleotide is 20 nucleobases in length.

67. (Previously Presented) The chimeric antisense oligonucleotide of claim 58, wherein the chimeric antisense oligonucleotide comprises:

a 5' wing segment consisting of five linked 2'-O-methoxyethyl nucleotides;

a 3' wing segment consisting of five linked 2'-O-methoxyethyl nucleotides;

a gap segment consisting of ten 2'-deoxynucleotides positioned between the 5' wing segment and the 3' wing segment;

wherein each internucleoside linkage is a phosphorothioate internucleotide linkages, and wherein each cytosine is a 5-methylcytosine.